Nvidia’s results, Tesla’s European sales, Japan trade - what’s moving markets
NEW YORK - Curanex Pharmaceuticals Inc. (NASDAQ:CURX), a developmental stage pharmaceutical company focused on botanical drugs for inflammatory diseases, has priced its initial public offering at $4.00 per share, according to a company statement released Tuesday. InvestingPro analysis shows the company maintains a Fair financial health rating, though it currently operates at a loss with negative earnings per share of $0.02.
The firm commitment offering consists of 3,750,000 shares of common stock, generating gross proceeds of $15 million before deducting underwriting discounts and offering expenses. According to InvestingPro data, the company maintains a healthy current ratio of 3.61, indicating strong short-term liquidity. Subscribers can access 6 additional key ProTips about CURX’s financial position.
Shares of Curanex are expected to begin trading on the Nasdaq Capital Market Tuesday under the ticker symbol "CURX." The offering is expected to close on August 27, 2025, subject to customary closing conditions.
The company has granted underwriters a 45-day option to purchase up to an additional 562,500 shares at the public offering price, less underwriting discounts and expenses.
Proceeds will fund development of the company’s lead product candidate, Phyto-N, for treating ulcerative colitis, including FDA-required toxicology and pharmacokinetic studies, preparation of an Investigational New Drug application, and general corporate purposes. The funding comes at a crucial time, as financial metrics from InvestingPro indicate the company’s debt-to-equity ratio stands at 0.8, while maintaining negative free cash flow in the last twelve months.
Dominari Securities LLC is serving as lead underwriter, with Pacific Century Securities LLC and Revere Securities LLC acting as co-underwriters.
Curanex’s lead candidate, Phyto-N, is a botanical extract from a single plant with anti-inflammatory properties. The company reports it has been used to treat thousands of patients with inflammatory diseases over 30 years in China.
The offering is being made through a prospectus filed with the Securities and Exchange Commission as part of a registration statement that was declared effective on August 12, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.